Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Research & Development (2022 - 2024)

Opus Genetics (IRD) has disclosed Research & Development for 5 consecutive years, with $1.8 million as the latest value for Q3 2014.

  • On a quarterly basis, Research & Development rose 133.56% to $1.8 million in Q3 2014 year-over-year; TTM through Sep 2014 was $43.3 million, a 1616.31% increase, with the full-year FY2022 number at $14.4 million, down 5.39% from a year prior.
  • Research & Development was $1.8 million for Q3 2014 at Opus Genetics, up from $1.7 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $38.5 million in Q4 2013 to a low of $265695.0 in Q4 2012.
  • A 5-year average of $5.7 million and a median of $1.5 million in 2010 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 14402.21% in 2013; the steepest drop was 97.77% in 2013.
  • Opus Genetics' Research & Development stood at $1.5 million in 2010, then rose by 0.26% to $1.5 million in 2011, then crashed by 82.11% to $265695.0 in 2012, then skyrocketed by 14402.21% to $38.5 million in 2013, then plummeted by 95.26% to $1.8 million in 2014.
  • Per Business Quant, the three most recent readings for IRD's Research & Development are $1.8 million (Q3 2014), $1.7 million (Q2 2014), and $1.3 million (Q1 2014).